Transcriptomics

Dataset Information

0

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma [scRNA-seq]


ABSTRACT: Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but clinical benefit is limited by intrinsic and acquired resistance. LUAD predominantly arises from alveolar type 2 (AT2) cells, which function as facultative alveolar stem cells by self-renewing and replacing alveolar type 1 (AT1) cells. Using genetically engineered mouse models, patient-derived xenografts, and patient samples we found inhibition of KRAS promotes transition to a quiescent AT1-like cancer cell state in LUAD tumors. Similarly, suppressing Kras induced AT1 differentiation of wild-type AT2 cells upon lung injury. The AT1-like LUAD cells exhibited high growth and differentiation potential upon treatment cessation, whereas ablation of the AT1-like cells robustly improved treatment response to KRAS inhibitors. Our results uncover an unexpected role for KRAS in promoting intra-tumoral heterogeneity and suggest targeting alveolar differentiation may augment KRAS-targeted therapies in LUAD.

ORGANISM(S): Mus musculus

PROVIDER: GSE246481 | GEO | 2023/11/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-11-01 | GSE246480 | GEO
2023-05-04 | GSE231679 | GEO
2023-05-04 | GSE231678 | GEO
2023-05-04 | GSE231675 | GEO
2023-05-04 | GSE231674 | GEO
2023-05-04 | GSE231671 | GEO
2023-05-04 | GSE231677 | GEO
2023-05-04 | GSE231676 | GEO
2013-04-15 | E-GEOD-38570 | biostudies-arrayexpress
2013-04-15 | E-GEOD-38569 | biostudies-arrayexpress